Cameco Announces Preliminary 2016 Earnings Expectations and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
108
Cameco Announces Preliminary 2016 Earnings Expectations and Operational Changes Planned for 2017

SASKATOON, SASKATCHEWAN--(Marketwired - Jan. 17, 2017) -

ALL AMOUNTS ARE STATED IN CDN $ (UNLESS NOTED)

Cameco (TSX:CCO) (NYSE:CCJ) is today announcing earnings expectations for its year ended December 31, 2016 and operational changes planned for 2017.

While it is not our usual practice to disclose earnings expectations, we are announcing our earnings expectations for 2016 in advance of our participation in upcoming investor conferences due to the significant discrepancy between analyst earnings estimates and our current expectations.

"Our current earnings expectations are not reflective of the strength of our core uranium business, which saw us achieve our outlook for delivery volumes at a realized price 83% higher than the current spot price," said president and CEO, Tim Gitzel. "The current earnings expectations do however reflect the consequences of a continued weak uranium market and our resolve to make the necessary decisions to defend and preserve our core uranium business for the long-term benefit of our stakeholders."

As expected, Cameco delivered 31.5 million pounds of uranium at an average realized price of $54.46 per pound in 2016. Also, we do not currently expect that any changes to the financial outlook for 2016 presented in the table on page 13 of our third quarter Management's Discussion and Analysis (our 2016 Financial Outlook Information) will have a material impact on our actual 2016 earnings. However, subject to completion of our quarterly financial close process, annual audit and approval of the 2016 consolidated financial statements by Cameco's board of directors, we expect to report an IFRS net loss for 2016 due in part to asset impairments resulting from fair market value assessments at year end. We expect our adjusted net earnings for 2016 will be significantly lower than analysts' earnings estimates. In presenting our adjusted net earnings, we expect to make total adjustments to net earnings between approximately $180 million and $220 million after-tax ($0.45 to $0.56 per share).

Cameco's full annual results will be released after markets close on February 9, 2017.

As previously reported, Cameco implemented a number of strategic initiatives in 2016 intended to strengthen our core business and enhance financial performance over time. These initiatives include the suspension of production at the Rabbit Lake operation and curtailment of our U.S. mining operations; signing of a collaboration agreement with the aboriginal communities located near our Saskatchewan operations; restructuring of our NUKEM segment and corporate office departments and consolidation of office space. Our legal costs related to our tax dispute with the Canada Revenue Agency (CRA) also increased as we prepared our case to be heard in the Tax Court of Canada, which started in October. The total estimated cost for all these items is approximately $120 million in 2016. These costs were partially offset by the $59 million of additional income generated by the termination of two long-term supply contracts in the third quarter of 2016. We also recorded an impairment charge for the Rabbit Lake mine and mill in conjunction with the suspension of production.

2017 Operational Changes

Cameco is planning a number of actions in 2017 intended to further reduce costs and improve efficiency at its uranium mining operations. The workforce at the McArthur River, Key Lake and Cigar Lake operations is expected to be reduced by approximately 10% or 120 employees in total. The reduction is planned to be conducted in stages and expected to be completed by the end of May 2017. Affected employees will be offered exit packages that include transition assistance.

Cameco also plans to implement changes to the air commuter service by which employees and contract workers get to and from the mine and mill sites in northern Saskatchewan, as well as work schedule changes to achieve additional cost savings. These changes will begin in April 2017 and are expected to be completed during 2018.

The workforce reduction and changes to air commuter service and work schedules planned at the Saskatchewan operations are not expected to impact production in 2017. However, due to cost cutting measures planned at Inkai, Cameco expects Inkai to produce almost 10% less in 2017 with Cameco's share being 3.1 million pounds. In 2016, Cameco's share of Inkai production was 3.3 million pounds.

Information regarding Cameco's uranium production plans for 2017 will be provided together with Cameco's full annual results for 2016 after markets close on February 9, 2017.

"We regret the impact of these decisions on affected employees and other stakeholders," said president and CEO, Tim Gitzel. "These are necessary actions to take in a uranium market that has remained weak and oversupplied for more than five years. While it is positive that we are starting to see other producers announce their intent to reduce supply, we have not yet seen an actual reduction in supply. Ultimately, it will be the return of both term demand and term contracting in a significant way that will signal that market fundamentals have turned more positive. While we expect that this demand and term contracting will come to the market at some point, it has not yet happened. These operational changes are part of our strategy to help us effectively manage the company through these low times and remain competitive, while positioning the company to benefit as the market improves."

Profile

Cameco is one of the world's largest uranium producers, a significant supplier of conversion services and one of two Candu fuel manufacturers in Canada. Our competitive position is based on our controlling ownership of the world's largest high-grade reserves and low-cost operations. Our uranium products are used to generate clean electricity in nuclear power plants around the world. We also explore for uranium in the Americas, Australia and Asia. Our shares trade on the Toronto and New York stock exchanges. Our head office is in Saskatoon, Saskatchewan.

Caution about forward-looking information

This news release includes statements considered to be forward-looking information or forward-looking statements under Canadian and U.S. securities laws (which we refer to as forward-looking information), including our current expectations regarding our 2016 earnings and adjustments thereto, our expectation that any changes to our 2016 Financial Outlook Information will not have a material impact on our actual 2016 earnings, our costs related to our strategic initiatives and our dispute with CRA for 2016, the expected cost savings to be achieved by our planned operational changes, our expected production levels, our expectations regarding future market demand for uranium and term contracting, and the ability of other strategic initiatives to strengthen our business and enhance financial performance.

This forward-looking information is based on a number of assumptions, including that: the information already available to us regarding our financial results for 2016, including asset impairment testing, is sufficiently complete and accurate to allow us to make a reasonable assessment of actual earnings results (and adjustments thereto), the extent of any changes to our 2016 Financial Outlook Information and costs related to our strategic initiatives and our dispute with CRA for 2016; that our planned workforce reductions and commuter service changes will achieve the expected cost savings and not impact 2017 uranium production at our Saskatchewan operations; that our other planned operational changes and strategic initiatives will successfully achieve their intended result; that market demand for uranium and term contracting will increase in the future; and that Inkai's 2017 mining and production plans succeed. This information is subject to a number of risks, including that: the completion of our quarterly financial close process may give rise to earnings results, adjustments to earnings, costs or asset impairments that are different from our current expectations; unforeseen factors may affect the significance of changes to the 2016 Financial Outlook Information and that we may not be successful in realizing the expected cost reductions and efficiency improvements from our planned workforce reduction, commuter service changes and other strategic initiatives; that our planned workforce reductions and commuter service changes impact 2017 uranium production at our Saskatchewan operations; market demand for uranium and term contracting levels remain stable or decrease; and Inkai's 2017 mining or production plans are delayed or do not succeed for any reason.

Please also refer to our annual information form, first quarter, second quarter and third quarter MD&A, and annual MD&A, which include a discussion of other material risks that could cause actual results to differ significantly from our current expectations, and other assumptions that we make in presenting forward-looking information.

The forward-looking information in this news release represents our current views, and can change significantly. It is subject to material risks and based upon assumptions. Actual results may be significantly different from what we currently expect. Forward-looking information is designed to help you understand management's current views, and may not be appropriate for other purposes. We will not necessarily update this information unless we are required to by securities laws.

Qualified Person

The above scientific and technical information related to Inkai was approved by Alain Mainville, director, mineral resources management for Cameco, who is a qualified person for the purpose of National Instrument 43-101.

Investor inquiries: Rachelle Girard (306) 956-6403 Media inquiries: Gord Struthers (306) 956-6593
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Sandler Partners Unveils 2025 Superstar Trip Destination

Updated Category News Views 179

Sandler Partners Unveils 2025 Superstar Trip Destination Sandler Partners is thrilled to reveal the highly anticipated location for its 2025 Superstar Trip, a special reward designed to honor Partners who have excelled in achieving their growth objectives for the year. The trip will take place at the stunning Susurros del Corazón Resort, located along the picturesque...

Continue Reading
e.l.f. Beauty Stock Insights: Understanding Market Trends Today

Updated Category News Views 309

Market Sentiment Surrounding e.l.f. Beauty Investors with substantial capital are showing a cautious approach towards e.l.f. Beauty (NYSE: ELF). This sentiment isn't just noise in the market; it reflects deeper strategies that should be on the radar of traders and analysts alike. There has been significant insight gleaned from public options activity which suggests that...

Continue Reading
Empowering Teens Through Free AI Bootcamp by Mark Cuban

Updated Category News Views 216

Empowering Teens Through Innovative AI Bootcamp Time is of the essence for high school students eager to launch their careers in technology with the Mark Cuban Foundation's Artificial Intelligence (AI) Bootcamp. Hosted by Girls Inc., this remarkable initiative opens doors for teens interested in the cutting-edge realm of AI. Applications for participation are set to close...

Continue Reading
BlackRock's Major Acquisition of Global Infrastructure Partners

Updated Category News Views 275

BlackRock Secures $12.5 Billion Deal The U.S. Federal Energy Regulatory Commission has recently approved BlackRock's substantial acquisition of Global Infrastructure Partners, valued at $12.5 billion. This approval is a pivotal moment for BlackRock as it seeks to broaden its reach within the infrastructure investment sector. Details of the Acquisition In this significant...

Continue Reading
Key Analyst Initiations Impacting Major Stocks This Week

Updated Category News Views 120

Recent Analyst Initiations: An Overview In the dynamic realm of stock trading, the insights of analysts can have a major impact on market trends. Recently, Wall Street has made significant adjustments to their ratings for several well-known stocks. Below, we summarize the latest analyst actions that may affect investor decisions this week. Arm Holdings plc (NASDAQ: ARM)...

Continue Reading